Abstract
Hemophilic patients are at an increased risk of hemorrhagic complications during surgical interventions with 25% to 32% occurrence in the postoperative period even if the target parameters of hemostasis were achieved. A clinical case of a 15 y/o patient with a moderate form of hemophilia A who had undergone extensive surgical intervention against the background of the use of the Nuwiq® (Simoctocog alfa (coagulation factor VIII human recombinant)) drug by Octapharma AG (Lachen, Bezirks March, Kanton Schwyz, Schweiz) is presented in this Article. The introduction of the drug had provided the normal hemostasis during the surgical intervention and contributed to the rapid recovery of the patient during the postoperative period.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
